latest update:
[TrialBase DB]

trial summary · NCT07717411

A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

Trial record from the TrialBase DB dataset, status RECRUITING, condition Alzheimer's Disease, sponsored by Hoffmann-La Roche. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07717411phase PHASE3enrollment 1600start 2026-11-30

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild cognitive impairment (MCI) due to AD or dementia due to AD.

Source record: https://clinicaltrials.gov/study/NCT07717411

Facts

registry idNCT07717411
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE3
study typeINTERVENTIONAL
lead conditionAlzheimer's Disease
sponsorHoffmann-La Roche
sponsor classINDUSTRY
enrollment1600
start date2026-11-30
primary completion2032-09-03
completion2032-09-03
results postednot reported

Conditions

  • Alzheimer's Disease

Interventions

  • Trontinemab
  • Placebo

Countries

  • Argentina
  • Australia
  • Canada
  • China
  • Taiwan
  • United Kingdom
  • United States

Intervention types: DRUG

Work with this record